ERYTECH (ERYP) Reports TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

Go back to ERYTECH (ERYP) Reports TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

February 8, 2021 1:30 AM EST

ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis                                                        

The Independent Data Monitoring Committee (IDMC) recommends trial to continue to final analysis, expected in Q4 2021No safety issues identified, consistent with observations in previous IDMC reviews

Lyon (France) and Cambridge, MA (U.S.), February 8, 2021 ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells,... More